Imunon (IMNN) Liabilities and Shareholders Equity (2010 - 2026)

Imunon (IMNN) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $8.0 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 16.86% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.1 million (up 44.96% YoY) and the FY2025 annual result came in at $12.3 million, up 26.46% from the prior year.
• Liabilities and Shareholders Equity eased to $8.0 million in Q1 2026, from $12.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $65.3 million in Q2 2022 to a low of $6.9 million in Q1 2025.
• A 5-year average of $26.9 million and a median of $18.1 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity plunged 66.26% — and 2025, when it advanced 26.46%.
• Tracing IMNN's Liabilities and Shareholders Equity over 5 years: stood at $44.0 million in 2022, then slumped by 50.16% to $21.9 million in 2023, then plunged by 55.67% to $9.7 million in 2024, then increased by 26.46% to $12.3 million in 2025, then slumped by 34.74% to $8.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $8.0 million (Q1 2026), $12.3 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.